Press Releases

CRANBURY, N.J., Nov. 16, 2010 /PRNewswire-FirstCall/ — Palatin Technologies, Inc. (NYSE Amex: PTN) today announced the appointment of Jeffrey D. Edelson, M.D., as Chief Medical Officer. Dr. Edelson has more than 15 years of leadership experience in the successful clinical development of medicines for the pharmaceutical and biotechnology industries.  Dr. Edelson has been responsible for …

Palatin Technologies Appoints Jeffrey D. Edelson, M.D., Chief Medical Officer Read More »

CRANBURY, N.J., Nov. 15, 2010 /PRNewswire-FirstCall/ — Palatin Technologies, Inc. (NYSE Amex: PTN), a biopharmaceutical company dedicated to the development of peptide mimetic and small molecule agonist compounds with a focus on melanocortin and natriuretic peptide receptor systems, today announced results for its first quarter ended September 30, 2010. Palatin reported a net loss of …

Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2011 Results; Teleconference and Webcast to be held on November 16, 2010 Read More »

CRANBURY, N.J., Nov. 12, 2010 /PRNewswire-FirstCall/ — Palatin Technologies, Inc. (NYSE Amex: PTN) will announce its first quarter, fiscal year 2011 financial results on Tuesday, November 16, 2010 before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on November …

Palatin Technologies, Inc. to Report Fiscal Year 2011 First Quarter Results; Teleconference and Webcast to be Held on November 16, 2010 Read More »

CRANBURY, N.J., Nov. 2, 2010 /PRNewswire/ — Palatin Technologies, Inc. (NYSE Amex: PTN), announced today that it has received $978,000 in grants under the Patient Protection and Affordable Care Act of 2010 (PPACA), with $847,000 available immediately and $131,000 available no later than 30 days after Palatin’s fiscal year ending June 30, 2011. The grants …

Palatin Technologies, Inc. Receives $978,000 in Grants Under the Patient Protection and Affordable Care Program Read More »

CRANBURY, N.J., Oct. 1 /PRNewswire-FirstCall/ — Palatin Technologies, Inc. (NYSE Amex: PTN) announced that it will be presenting at the 9th Annual BIO Investor Forum on Wednesday, October 6, 2010 at 8:00 AM PT.  Hosted by the Biotechnology Industry Organization (BIO), the 9th Annual BIO Investor Forum will take place October 5-6 at the Palace …

Palatin Technologies to Present at 9th Annual BIO Investor Forum Read More »

CRANBURY, N.J., Sept. 27 /PRNewswire-FirstCall/ — Palatin Technologies, Inc. (NYSE Amex: PTN), a biopharmaceutical company dedicated to the development of peptide, peptide mimetic and small molecule agonist compounds with a focus on melanocortin and natriuretic peptide receptor systems, today announced results for its fourth quarter and fiscal year ended June 30, 2010.  All share and …

Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2010 Results Teleconference and Webcast to be held on September 27, 2010 Read More »

CRANBURY, N.J., Sept. 24 /PRNewswire-FirstCall/ — Palatin Technologies, Inc. (NYSE Amex: PTN) today announced the realignment of its workforce and operations to reflect a strategic reassessment of its research and development activities and corporate objectives. As a result, Palatin will focus resources and efforts on clinical trials of bremelanotide for male and female sexual dysfunction …

Palatin Announces Strategic Realignment of Operations Read More »

CRANBURY, N.J., Sept. 22 /PRNewswire-FirstCall/ — Palatin Technologies, Inc. (NYSE Amex: PTN) will announce its fourth quarter, fiscal year 2010 financial results on Monday, September 27, 2010 before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on September 27, …

Palatin Technologies, Inc. to Report Fiscal Year 2010 Fourth Quarter Results; Teleconference and Webcast to be held on September 27, 2010 Read More »

CRANBURY, N.J., Sept. 10 /PRNewswire/ — Palatin Technologies, Inc. (NYSE Amex: PTN) announced that it will be presenting at the Rodman & Renshaw Annual Global Investment Conference / 12th Annual Healthcare Conference on Tuesday, September 14, 2010 at 10:50 AM ET.  The conference will take place September 12-15 at the New York Palace Hotel in …

Palatin Technologies to Present at Rodman & Renshaw Annual Global Investment Conference Read More »

CRANBURY, N.J., Aug. 17 /PRNewswire-FirstCall/ — Palatin Technologies, Inc. (NYSE Amex: PTN) today announced positive results of a Phase 1 clinical trial of subcutaneously administered bremelanotide, its melanocortin agonist drug candidate for treatment of male erectile dysfunction (ED) and female sexual dysfunction (FSD). The results demonstrate that with subcutaneous administration consistent therapeutic blood plasma levels …

Palatin Technologies, Inc. Announces Positive Safety Results in Subcutaneous Bremelanotide Trial in Men Read More »